Ajoy Oommen John (@ajoyojohn) header
Ajoy Oommen John (@ajoyojohn) profile picture

Medical Oncology, CMC Vellore | Solid tumors, clinical trials & dose-optimization research | Interested in access, equity & quality in cancer care

Vellore, India
Joined September 2020
Photo by Ajoy Oommen John (@ajoyojohn)Photo by Ajoy Oommen John (@ajoyojohn)
Honored to receive @ASCO @ConquerCancerFd Global Oncology Young Investigator Award #YIA. Privileged to be part of this inspiring group.Grateful to my mentors @todrashish and Dr Nithya Ramnath. Indebted to @OffCMCVellore for the support, especially @MathewsVikram and Dr Solomon.
Congratulations to this year's class of Conquer Cancer Grant and Award recipients! We can't wait to celebrate with you at #ASCO24! Full list of recipients: brnw.ch/21wKdIf
7
3
2
31
2,707
Ajoy Oommen John retweeted
Neolocus2 RCT comparing PCm+IO to DCF is recruiting fast for borderline resectable HNSCC..led by @ajoyojohn happy for our patients who now have a very effective and tolerable regimen..
NeoLOCUS vs PCm/DCF | Phase II Promise vs Phase III Evidence! Two Indian studies exploring neoadjuvant strategies in oral cavity cancer. 🔹 NeoLOCUS | Marimuthu et al. Single-arm Phase II (n=34), incorporating low-dose nivolumab + chemotherapy + oral metronomic therapy. ORR 66.6% | Surgery 87.9% | 2-year OS 67.1%. 🔹 PCm vs DCF | Noronha et al. Randomized Phase III (n=475). PCm demonstrated OS non-inferiority to DCF, with higher response and surgery rates and substantially less grade ≥3 toxicity (43.2% vs 86.4%). 🎯 Take-home: PCm has randomized Phase III evidence. NeoLOCUS is promising but needs Phase III validation. ⚠️ Different populations and study designs — cross-trial comparisons are not head-to-head. References: Marimuthu et al.; Noronha et al. ESMO 2026. @myESMO @OncoAlert @larvol #MVOnco #ESMO2026 #HeadNeckCancer #OralCancer #Immunotherapy
4
9
639
Ajoy Oommen John retweeted
🎉 Congratulations to Ruth Sudha Moses, a recipient of the IASLC Adi F. Gazdar Fellowship! #LungCancer #LungCancerResearch
2
4
24
1,203
Ajoy Oommen John retweeted
Pleased to present our study at #ASCOBT26. We showed 2step DPD phenotyping + targeted DPYD genotyping improved identification of patients at risk of severe 5-FU toxicity while reducing unnecessary genotyping. Grateful to Dr. Binu Susan, @ajoyojohn, @todrashish & @OffCMCVellore.
2
4
181
So excited to see the beautiful narrative”Unfinished Frock” emerge as one of our most downloaded articles in 2026 ⁦@JCOGO_ASCO! Congratulations🥳 to Dr Praveen Kumar Marimuthu @drmpk91⁩ ⁦@OffCMCVellore⁩ ascopubs.org/doi/10.1200/GO-…
1
7
1
19
1,540
Ajoy Oommen John retweeted
Proud to be part of this collaborative prospective study published in @TheLancet Regional Health - Southeast Asia, from @OffCMCVellore, led by @Anuradha28980. Can structured reporting change outcomes? We show how a structured CT-based decision-support tool (CT-PAUSE) can improve MDT decision-making and surgical triage in advanced ovarian cancer - with ~89% complete cytoreduction in selected patients. thelancet.com/journals/lanse… #Radiology #Oncology #Globalhealth @CMCVellore @VelloreRadRover
2
2
144
Ajoy Oommen John retweeted
Borderline resectable oral cavity cancer is a surgical dilemma. Can chemo-immunotherapy increase operability? A new Phase II trial suggests yes. 🧪 NeoLOCUS trial (Lancet Regional Health SE Asia) Regimen: Carboplatin + nab-paclitaxel + low-dose nivolumab •oral metronomic therapy (methotrexate + celecoxib + erlotinib) 🎯 Population Borderline resectable OSCC n = 34 📊 Key results • ORR: 66.6% • R0 resection after 2 cycles: 75.7% • Overall surgical conversion: 90.3% • Major pathological response: 41% • pCR: 13.8% 🧬 Interesting biology Good responders showed reduction in FOXP3+ Tregs, suggesting immune-microenvironment modulation. ⚠️ Safety Grade ≥3 toxicity: 14.7% No treatment-related deaths. 💡 Why this matters Borderline OSCC often fails surgery after standard NACT. This low-dose IO + metronomic + chemo strategy may offer an affordable outpatient approach in LMIC settings. But this is single-arm Phase II → randomized validation needed. #OncoTwitter #MedTwitter #HeadAndNeckCancer #Immunotherapy @OncoAlert @ASCO @myESMO @drmpk91 @todrashish @ajoyojohn
4
13
42
3,593
Ajoy Oommen John retweeted
📢Elated to share our new paper from @OffCMCVellore in The Lancet Regional Health- SE Asia. NeoLOCUS Phase II trial: short regimen of low-dose nivolumab+carbo/nab-pacli+ OMCT👉~90% surgical conversion borderline resectable OCSCC. Congrats to @todrashish @drmpk91 for leading!
Excited to share that our phase 2 trial #NeoLOCUS is now out in @LancetRH_SEAsia! A collective effort from the Head & Neck team @OffCMCVellore led by @todrashish We report R0 rates, ORR, safety, survival outcomes, tumor immune microenvironment change🧵👇 thelancet.com/journals/lanse…
4
5
20
1,112
Ajoy Oommen John retweeted
Proud to share my training roots at @OffCMCVellore with @sonpavde — a leader advancing GU oncology. It was a pleasure meeting you! #ASCOGU26
1
2
9
373
Ajoy Oommen John retweeted
Huge Congratulations to @DarwinAnil @todrashish, MedOnc and Clin Pharm @OffCMCVellore on presenting our phase II #TOCAN trial at @myESMO #ESMOAsia25 Efficacy, PK analysis of thrice weekly #osimertinib + chemo in EGFRm #lungadenocarcinoma. ✨ORR ~90% ☀️18 mo PFS : 78.8% OS: 89.5%
5
6
1
35
2,159
Ajoy Oommen John retweeted
Jaw-dropping ctDNA data in rectal cancer thanks to the GALAXY study (the gift that keeps on giving)🤯🧬. This prospective cohort from Japan looked at stage II–III rectal cancer treated with upfront surgery, no neoadjuvant therapy. It gives us one of the cleanest looks yet at postoperative ctDNA and who actually benefits from adjuvant chemo. 🩸 In the MRD window (2–10 weeks postop): • 14% ctDNA positive → very high recurrence risk (HR ~10) • 86% ctDNA negative → excellent outcomes with or without adjuvant therapy 💊 The key finding: Among ctDNA-negative patients, adjuvant chemotherapy did not show a statistically significant DFS benefit (HR 0.59, p = 0.21), 2 year DFS 86.1% vs 84.2%. The direction favors treatment, but the study didn't demonstrate benefit with very wide confidence intervals due to low numbers of ctDNA + patients (35). The HR implies improvement, but the curves overlap... In contrast, ctDNA-positive patients clearly benefited from adjuvant chemo (HR 0.28). 📈 Serial testing mattered. Patients who remained ctDNA negative did extremely well, while those who converted to positive had a sharp rise in recurrence risk. Takeaway: This strongly questions the value of adjuvant chemotherapy in ctDNA negative rectal patients after upfront surgery irrespective of stage. Looking forward to discussing at #GI26 (and why ctDNA still isn't in NCCN CRC guidelines). @OncoAlert @TheGutOncLab
5
49
3
149
15,796
Ajoy Oommen John retweeted
Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers in @ESMO_Open. EV shows activity especially in patients with esophageal squamous cell carcinoma, with expected safety profile. esmoopen.com/article/S2059-7…
5
12
2,668
🎓 An absolute honour to graduate from the 1st batch of DM Medical Oncology @OffCMCVellore alongside an exceptional group of colleagues @ajoyojohn @jtgeorgy @Harikri44884728 Prashant & our ever-inspiring mentor @todrashish Grateful & humbled to be a small part of MONC, CMC 🤍💙
2
8
411
Ajoy Oommen John retweeted
An interesting venue (@Cancer_Cell!) for this randomized phase 3 trial in #PancreaticCancer. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer cell.com/cancer-cell/fulltex… Sequential NAT v upfront surgery in resectable PDAC!
2
26
2
64
14,005
Ajoy Oommen John retweeted
Bloomberg @business (Global, NY) @RobertLangreth recently featured our work from @OffCMCVellore Medical Oncology & Haematology and @TataMemorial: low-dose immunotherapy and potential for equitable cancer care. What if 1/6th the dose works just as well? bloomberg.com/features/2025-…
3
17
1
33
3,618
Excited to see @business highlight ongoing efforts to optimize cancer treatment through dose-modification strategies. Grateful that some of our work is acknowledged as part of this important global conversation. 👇
1
2
2
230
@business explores use of lower-dose regimens of high-cost cancer drugs: 📊 Emerging clinical evidence supporting efficacy at reduced doses 🌍 Critical implications for access in resource-limited settings 🧪 Underscores the need for rigorous, collaborative research.
86